We spent the day at Bio2008. The turnout seemed pretty good, and the conference was spectacularly well organized. Special Aminopop shout-out to Erin Reese for arranging a press pass.
What comes to mind, while we’re still catching our breath: Biotech industry people are healthier, better dressed and better groomed than people in infotech — we haven’t seen that many ties and perfect creases at a trade show since 1985. The gargantuan exhibition hall was jammed with booths. But, unlike an infotech trade show, a whole lot of them — maybe even a majority — weren’t fronting for individual biotech companies… but instead for various consortia (government sponsored and commercial associations), biotech industry-stimulating efforts of various nations (“Biotechnology in Sweden!” “The Malaysian Miracle!” etc.), and … law firms. A ton of them. All of them wanting to help you protect your valuable intellectual property. Probably a good sign; to paraphrase Stewart Brand, if you want to find out where the action is in a culture, follow the lawyers. Based on the showing of litigants at Bio2008, there’s evidently a ton of cultural action in Biotech.
The one major disappointment was the almost singular focus on pharma. Despite the conference’s slogan of “Heal, Fuel, Feed The Planet”, there was little feeding or fueling in evidence. Amazingly, the Wednesday Ernst&Young supersession (okay, so we left after 90 minutes, so sue us if we missed something) didn’t contain a single reference to agriculture or biofuels. This is a little weird, and very un-Aminopop to boot; we’re pretty certain the first world-changing Biotech killer app isn’t going to be a drug. Yet, to outward appearances at Bio2008, Biotech seems to be all about antibodies and small-molecule drugs. Oh, and litigation.
There were plenty of exceptions, though. We did turn up a whole lot of fun stuff, which we’ll write up over the next few days — hands-on fun stuff like nanotech fluorescence tags, a desktop microfluidics rig, and a korean hand-held PCR unit that looks like a klunky iPod. We also collected a pile of fun booth-bait tchochkes we’ll roll out in separate post.
All in all, though, the show left us yearning for that Juan Enriques-brand vision, enthusiasm and irreverent prognostication we find so charming and, well… fun. Maybe next year. Right now, Biotech people seem to be buttoned up a little tightly because of capitalization cycles and gloomy equity markets. We think they need another good 2001-style bubble to bring them out of their shells a bit.
More later.